Trial Profile

Phase III study of abicipar in patients with Diabetic macular edema (DME)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abicipar pegol (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use
Sponsors AbbVie; Allergan

Most Recent Events

09 May 2019 According to a Molecular Partners AG media release, Allergan plans to launch this trial in 2020.
07 Feb 2019 According to a Molecular Partners AG media release, Allergan intends to initiate this study in H2 2019.
08 Feb 2018 According to a Molecular Partners AG media release, company expects to initiate this trial in H2 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com